Advanced melanoma
Showing 51 - 75 of >10,000
Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used
Completed
- Melanoma
- Non-Interventional
-
Boston, MassachusettsLocal Institution
Jan 27, 2022
Melanoma (Skin) Trial in Philadelphia (89Zr-Df-IAB22M2C PET/CT)
Enrolling by invitation
- Melanoma (Skin)
- 89Zr-Df-IAB22M2C PET/CT
-
Philadelphia, PennsylvaniaPerleman Center for Advanced Medicine
May 31, 2022
Metastatic Melanoma Trial (PV-001-DC)
Not yet recruiting
- Metastatic Melanoma
- PV-001-DC
- (no location specified)
Aug 4, 2022
Melanoma Trial in Beijing (tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin)
Not yet recruiting
- Melanoma
- tunlametinib
- paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Aug 15, 2023
Nivolumab Monotherapy or in Combination With Ipilimumab in
Active, not recruiting
- Melanoma
-
Essen, GermanyLocal Institution
Apr 25, 2022
Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)
Not yet recruiting
- Acral Melanoma
- camrelizumab+apatinib+TMZ
- +2 more
- (no location specified)
Mar 16, 2023
Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma Trial in Shanghai (Phase I
Not yet recruiting
- Has a Pathologically Documented Unresectable Locally Advanced or Metastatic Solid Tumor or Lymphoma
- Phase I dose escalation
- +3 more
-
Shanghai, Shanghai, ChinaFudan Cancer Hospital
Apr 24, 2023
Melanoma (Skin), Solid Tumor Trial in Australia, United States (PI-88)
Completed
- Melanoma (Skin)
- Unspecified Adult Solid Tumor, Protocol Specific
-
Aurora, Colorado
- +4 more
Jun 21, 2022
Melanoma Trial in Pittsburgh (Pembrolizumab, Vemurafenib, Cobimetinib)
Terminated
- Melanoma
- Pembrolizumab
- +2 more
-
Pittsburgh, PennsylvaniaUPMC Cancer Center Hillman Cancer Center
Dec 10, 2021
Melanoma, NSCLC, Colorectal Cancer Trial in United States (LYL845)
Recruiting
- Melanoma
- +2 more
- LYL845
-
Columbus, Ohio
- +3 more
Dec 19, 2022
Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma
Recruiting
- Clinical Stage III Cutaneous Melanoma AJCC v8
- +41 more
- Ipilimumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 11, 2022
Advanced Mucosal Melanoma Trial (Envafolimab combined with recombinant human endostatin and first-line chemo)
Not yet recruiting
- Advanced Mucosal Melanoma
- Envafolimab combined with recombinant human endostatin and first-line chemotherapy
- (no location specified)
Sep 15, 2023
Advanced Melanoma Trial in Beijing (JS001+Imatinib mesylate)
Recruiting
- Advanced Melanoma
- JS001+Imatinib mesylate
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Mar 2, 2022
Efficacy of Prolgolimab in Advanced Melanoma in Routine Clinical
Recruiting
- Advanced Melanoma
-
Moscow, Russian FederationN.N. Blokhin National Medical Research Center of Oncology
Nov 3, 2021
Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation Trial in Tampa (Encorafenib Pill, Binimetinib Pill, Nivolumab)
Recruiting
- Melanoma Stage III
- +2 more
- Encorafenib Pill
- +2 more
-
Tampa, FloridaMoffitt Cancer Center
May 27, 2022
Melanoma (Skin) Trial in Philadelphia (sorafenib tosylate, temozolomide)
Completed
- Melanoma (Skin)
- sorafenib tosylate
- temozolomide
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jun 13, 2022
Advanced Uveal Melanoma, Metastatic Uveal Melanoma, Unresectable Uveal Melanoma Trial (BRD4 Inhibitor PLX2853, Trametinib,
Not yet recruiting
- Advanced Uveal Melanoma
- +2 more
- BRD4 Inhibitor PLX2853
- +4 more
- (no location specified)
Jan 9, 2023
Tumor Skin, Metastatic Melanoma, Melanoma Trial in Orlando, Louisville (OBX-115)
Active, not recruiting
- Tumor Skin
- +2 more
- OBX-115
-
Orlando, Florida
- +1 more
Sep 28, 2023
